Real-World Effectiveness and Usage of rFIXFc in Haemophilia B: Final Paediatric Data from the B-MORE Study

• EAHAD •
• 6 February, 2026 •
• •

Efanesoctocog Alfa Prophylaxis for People with Severe Haemophilia A: Third Interim Results from the XTEND-ed Long-Term Extension Study

Sophie Susen, Anthony KC Chan, Pratima Chowdary, Stephanie P’ng, Manuela Albisetti, Keiji Nogami, Karin Fijnvandraat, Jennifer Dumont , Elena Santagostino, Sriya Gunawardena, Mahnouch Georget, Lynn Malec

• EAHAD •
• 4 February, 2026 •
• •

Physical Activity and Efficacy in Patients with Severe Haemophilia A Treated with Efanesoctocog Alfa: 12-Month Interim Results from FREEDOM

Jan Astermark, Olga Benitez Hidalgo, Hervé Chambost, Antonio Coppola, Shamil Sadikhov, Jenny Björkqvist, Markus Fusser, Niamh O’Connell

Available materials

• EAHAD •
• 4 February, 2026 •
• •

Long-Term Clinical Outcomes of Efanesoctocog Alfa in Patients with Severe Haemophilia A: European Results from the Third Interim Analysis of XTEND-ed

Sophie Susen, Manuela Albisetti, Karin Fijnvandraat, Elena Santagostino, Mahnouch Georget, Meredith C. Foster, Pratima Chowdary

Available materials

• EAHAD •
• 4 February, 2026 •
• •

Treatment of Bleeding Episodes with Efanesoctocog Alfa in Adults, Adolescents, and Children with Severe Haemophilia A: Third Interim Analysis of the XTEND-ed Long-term Extension Study

Johannes Oldenburg, Manuel Carcao , Sandrine Meunier, Nobuaki Suzuki, María Teresa Álvarez Román, Graham Neill, Sriya Gunawardena, Lydia Abad-Franch, Meredith Foster, Linda Bystrická, Angela Weyand

Available materials